The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Metabolomics Biomarker-Global Market Insights and Sales Trends 2024
Synopsis
The global Metabolomics Biomarker market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Metabolomics Biomarker in various end use industries. The expanding demands from the Toxicological studies, Drug testing, Cancer and Cardiovascular disorders, are propelling Metabolomics Biomarker market. Protein Marker, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Nucleic Acid Marker segment is estimated at % CAGR for the next seven-year period.
Asia Pacific shows high growth potential for Metabolomics Biomarker market, driven by demand from China, the second largest economy with some signs of stabilising, the Metabolomics Biomarker market in China is forecast to reach US$ million by 2029, trailing a CAGR of % over the 2023-2029 period, while the U.S. market will reach US$ million by 2029, exhibiting a CAGR of % during the same period.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Metabolomics Biomarker, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Metabolomics Biomarker market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Metabolomics Biomarker market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Metabolomics Biomarker sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Metabolomics Biomarker covered in this report include Biocrates Life Sciences, Biomark Diagnostics, Chenomx, Creative Proteomics, Evotec, Human Metabolome Technologies, Merck, Metabolomic Diagnostics and Metabolon, etc.
The global Metabolomics Biomarker market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Biocrates Life Sciences
Biomark Diagnostics
Chenomx
Creative Proteomics
Evotec
Human Metabolome Technologies
Merck
Metabolomic Diagnostics
Metabolon
Ovid Therapeutics
Global Metabolomics Biomarker market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Metabolomics Biomarker market, Segment by Type:
Protein Marker
Nucleic Acid Marker
Global Metabolomics Biomarker market, by Application
Toxicological studies
Drug testing
Cancer
Cardiovascular disorders
Neurological disorders
Inborn errors of metabolism
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Metabolomics Biomarker companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
The global Metabolomics Biomarker market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Metabolomics Biomarker in various end use industries. The expanding demands from the Toxicological studies, Drug testing, Cancer and Cardiovascular disorders, are propelling Metabolomics Biomarker market. Protein Marker, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Nucleic Acid Marker segment is estimated at % CAGR for the next seven-year period.
Asia Pacific shows high growth potential for Metabolomics Biomarker market, driven by demand from China, the second largest economy with some signs of stabilising, the Metabolomics Biomarker market in China is forecast to reach US$ million by 2029, trailing a CAGR of % over the 2023-2029 period, while the U.S. market will reach US$ million by 2029, exhibiting a CAGR of % during the same period.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Metabolomics Biomarker, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Metabolomics Biomarker market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Metabolomics Biomarker market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Metabolomics Biomarker sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Metabolomics Biomarker covered in this report include Biocrates Life Sciences, Biomark Diagnostics, Chenomx, Creative Proteomics, Evotec, Human Metabolome Technologies, Merck, Metabolomic Diagnostics and Metabolon, etc.
The global Metabolomics Biomarker market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Biocrates Life Sciences
Biomark Diagnostics
Chenomx
Creative Proteomics
Evotec
Human Metabolome Technologies
Merck
Metabolomic Diagnostics
Metabolon
Ovid Therapeutics
Global Metabolomics Biomarker market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Metabolomics Biomarker market, Segment by Type:
Protein Marker
Nucleic Acid Marker
Global Metabolomics Biomarker market, by Application
Toxicological studies
Drug testing
Cancer
Cardiovascular disorders
Neurological disorders
Inborn errors of metabolism
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Metabolomics Biomarker companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Metabolomics Biomarker
1.1 Metabolomics Biomarker Market Overview
1.1.1 Metabolomics Biomarker Product Scope
1.1.2 Metabolomics Biomarker Market Status and Outlook
1.2 Global Metabolomics Biomarker Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Metabolomics Biomarker Market Size by Region (2018-2029)
1.4 Global Metabolomics Biomarker Historic Market Size by Region (2018-2023)
1.5 Global Metabolomics Biomarker Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Metabolomics Biomarker Market Size (2018-2029)
1.6.1 North America Metabolomics Biomarker Market Size (2018-2029)
1.6.2 Europe Metabolomics Biomarker Market Size (2018-2029)
1.6.3 Asia-Pacific Metabolomics Biomarker Market Size (2018-2029)
1.6.4 Latin America Metabolomics Biomarker Market Size (2018-2029)
1.6.5 Middle East & Africa Metabolomics Biomarker Market Size (2018-2029)
2 Metabolomics Biomarker Market by Type
2.1 Introduction
2.1.1 Protein Marker
2.1.2 Nucleic Acid Marker
2.2 Global Metabolomics Biomarker Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Metabolomics Biomarker Historic Market Size by Type (2018-2023)
2.2.2 Global Metabolomics Biomarker Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Metabolomics Biomarker Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Metabolomics Biomarker Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Metabolomics Biomarker Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Metabolomics Biomarker Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Metabolomics Biomarker Revenue Breakdown by Type (2018-2029)
3 Metabolomics Biomarker Market Overview by Application
3.1 Introduction
3.1.1 Toxicological studies
3.1.2 Drug testing
3.1.3 Cancer
3.1.4 Cardiovascular disorders
3.1.5 Neurological disorders
3.1.6 Inborn errors of metabolism
3.2 Global Metabolomics Biomarker Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Metabolomics Biomarker Historic Market Size by Application (2018-2023)
3.2.2 Global Metabolomics Biomarker Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Metabolomics Biomarker Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Metabolomics Biomarker Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Metabolomics Biomarker Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Metabolomics Biomarker Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Metabolomics Biomarker Revenue Breakdown by Application (2018-2029)
4 Metabolomics Biomarker Competition Analysis by Players
4.1 Global Metabolomics Biomarker Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Metabolomics Biomarker as of 2022)
4.3 Date of Key Players Enter into Metabolomics Biomarker Market
4.4 Global Top Players Metabolomics Biomarker Headquarters and Area Served
4.5 Key Players Metabolomics Biomarker Product Solution and Service
4.6 Competitive Status
4.6.1 Metabolomics Biomarker Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Biocrates Life Sciences
5.1.1 Biocrates Life Sciences Profile
5.1.2 Biocrates Life Sciences Main Business
5.1.3 Biocrates Life Sciences Metabolomics Biomarker Products, Services and Solutions
5.1.4 Biocrates Life Sciences Metabolomics Biomarker Revenue (US$ Million) & (2018-2023)
5.1.5 Biocrates Life Sciences Recent Developments
5.2 Biomark Diagnostics
5.2.1 Biomark Diagnostics Profile
5.2.2 Biomark Diagnostics Main Business
5.2.3 Biomark Diagnostics Metabolomics Biomarker Products, Services and Solutions
5.2.4 Biomark Diagnostics Metabolomics Biomarker Revenue (US$ Million) & (2018-2023)
5.2.5 Biomark Diagnostics Recent Developments
5.3 Chenomx
5.3.1 Chenomx Profile
5.3.2 Chenomx Main Business
5.3.3 Chenomx Metabolomics Biomarker Products, Services and Solutions
5.3.4 Chenomx Metabolomics Biomarker Revenue (US$ Million) & (2018-2023)
5.3.5 Creative Proteomics Recent Developments
5.4 Creative Proteomics
5.4.1 Creative Proteomics Profile
5.4.2 Creative Proteomics Main Business
5.4.3 Creative Proteomics Metabolomics Biomarker Products, Services and Solutions
5.4.4 Creative Proteomics Metabolomics Biomarker Revenue (US$ Million) & (2018-2023)
5.4.5 Creative Proteomics Recent Developments
5.5 Evotec
5.5.1 Evotec Profile
5.5.2 Evotec Main Business
5.5.3 Evotec Metabolomics Biomarker Products, Services and Solutions
5.5.4 Evotec Metabolomics Biomarker Revenue (US$ Million) & (2018-2023)
5.5.5 Evotec Recent Developments
5.6 Human Metabolome Technologies
5.6.1 Human Metabolome Technologies Profile
5.6.2 Human Metabolome Technologies Main Business
5.6.3 Human Metabolome Technologies Metabolomics Biomarker Products, Services and Solutions
5.6.4 Human Metabolome Technologies Metabolomics Biomarker Revenue (US$ Million) & (2018-2023)
5.6.5 Human Metabolome Technologies Recent Developments
5.7 Merck
5.7.1 Merck Profile
5.7.2 Merck Main Business
5.7.3 Merck Metabolomics Biomarker Products, Services and Solutions
5.7.4 Merck Metabolomics Biomarker Revenue (US$ Million) & (2018-2023)
5.7.5 Merck Recent Developments
5.8 Metabolomic Diagnostics
5.8.1 Metabolomic Diagnostics Profile
5.8.2 Metabolomic Diagnostics Main Business
5.8.3 Metabolomic Diagnostics Metabolomics Biomarker Products, Services and Solutions
5.8.4 Metabolomic Diagnostics Metabolomics Biomarker Revenue (US$ Million) & (2018-2023)
5.8.5 Metabolomic Diagnostics Recent Developments
5.9 Metabolon
5.9.1 Metabolon Profile
5.9.2 Metabolon Main Business
5.9.3 Metabolon Metabolomics Biomarker Products, Services and Solutions
5.9.4 Metabolon Metabolomics Biomarker Revenue (US$ Million) & (2018-2023)
5.9.5 Metabolon Recent Developments
5.10 Ovid Therapeutics
5.10.1 Ovid Therapeutics Profile
5.10.2 Ovid Therapeutics Main Business
5.10.3 Ovid Therapeutics Metabolomics Biomarker Products, Services and Solutions
5.10.4 Ovid Therapeutics Metabolomics Biomarker Revenue (US$ Million) & (2018-2023)
5.10.5 Ovid Therapeutics Recent Developments
6 North America
6.1 North America Metabolomics Biomarker Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Metabolomics Biomarker Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Metabolomics Biomarker Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Metabolomics Biomarker Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Metabolomics Biomarker Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Metabolomics Biomarker Market Dynamics
11.1 Metabolomics Biomarker Industry Trends
11.2 Metabolomics Biomarker Market Drivers
11.3 Metabolomics Biomarker Market Challenges
11.4 Metabolomics Biomarker Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
